Summary of genotypic, immunophenotypic, and TCR-rearrangement and transcriptional results in classic M3 and hypogranular M3v APL and in M1/M2 and M4/M5 AML
. | M3 . | M3v . | M1 + M2 . | M4 + M5 . |
|---|---|---|---|---|
| No. | 21 | 15 | 21 (10 + 11) | 15 (3 + 12) |
| PML-RARA bcr3 (%) | 8/21 (38) | 9/15 (60) | NA | NA |
| FLT3-ITD (%) | 4/21 (19)† | 11/15 (73) | 4/20 (20)† | 2/15 (13)† |
| CD34+ (%) | 0/9 (0)‡ | 8/15 (53) | 13/20 (65) | 3/15 (20) |
| CD117+ (%) | 3/8 (38) | 9/15 (60) | 15/15 (100) | 6/12 (50) |
| cTdT+ (%) | 0/13 (0) | 3/13 (23) | 3/18 (17) | 0/15 (0)‡ |
| CD2+ (%) | 1/14 (7)‡ | 8/15 (53) | 2/20 (10)‡ | 1/15 (7)† |
| cCD3+ (%) | 0/12 (0) | 2/13 (15) | 3/17 (18) | 0/15 (0) |
| CD7+ (%) | 2/13 (15) | 4/13 (31) | 2/19 (10) | 2/15 (13) |
| Median PTCRA/ABL, % | 5.8 | 20.3 | 1.1† | < 0.1† |
| Median TEA-Cα/ABL, % | 1† | 10.2 | 2.3‡ | 0.7† |
| TCR rearrangement (%) | 1/17 (6) | 4/15 (27) | 0/18 (0)‡ | 1/11 (9) |
| CD2+, cCD3+, or CD7+ (%) | 0/12 (0)‡ | 5/13 (38) | 2/17 (12) | 0/15 (0)‡ |
| PTCRA/ABL more than 10%, TEA-Cα/ABL more than 10%, or TCR rearrangement (%) | 0/17 (0)† | 9/15 (60) | 0/18 (0)† | 0/9 (0)‡ |
. | M3 . | M3v . | M1 + M2 . | M4 + M5 . |
|---|---|---|---|---|
| No. | 21 | 15 | 21 (10 + 11) | 15 (3 + 12) |
| PML-RARA bcr3 (%) | 8/21 (38) | 9/15 (60) | NA | NA |
| FLT3-ITD (%) | 4/21 (19)† | 11/15 (73) | 4/20 (20)† | 2/15 (13)† |
| CD34+ (%) | 0/9 (0)‡ | 8/15 (53) | 13/20 (65) | 3/15 (20) |
| CD117+ (%) | 3/8 (38) | 9/15 (60) | 15/15 (100) | 6/12 (50) |
| cTdT+ (%) | 0/13 (0) | 3/13 (23) | 3/18 (17) | 0/15 (0)‡ |
| CD2+ (%) | 1/14 (7)‡ | 8/15 (53) | 2/20 (10)‡ | 1/15 (7)† |
| cCD3+ (%) | 0/12 (0) | 2/13 (15) | 3/17 (18) | 0/15 (0) |
| CD7+ (%) | 2/13 (15) | 4/13 (31) | 2/19 (10) | 2/15 (13) |
| Median PTCRA/ABL, % | 5.8 | 20.3 | 1.1† | < 0.1† |
| Median TEA-Cα/ABL, % | 1† | 10.2 | 2.3‡ | 0.7† |
| TCR rearrangement (%) | 1/17 (6) | 4/15 (27) | 0/18 (0)‡ | 1/11 (9) |
| CD2+, cCD3+, or CD7+ (%) | 0/12 (0)‡ | 5/13 (38) | 2/17 (12) | 0/15 (0)‡ |
| PTCRA/ABL more than 10%, TEA-Cα/ABL more than 10%, or TCR rearrangement (%) | 0/17 (0)† | 9/15 (60) | 0/18 (0)† | 0/9 (0)‡ |
Statistical significance between M3v and M3, M1/2, or M4/5 AML is indicated as ‡ if .001 < P < .05 and † if P ≤ .001. The 2 final rows summarize data. The number of cases expressing at least 2 of the stated phenotypic or genotypic characteristics is shown.
NA indicates not applicable